IRIS
LAZZARIN, ADRIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 962
NA - Nord America 762
AS - Asia 98
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 4
SA - Sud America 2
OC - Oceania 1
Totale 1.834
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 756
SE - Svezia 714
IT - Italia 144
CN - Cina 47
FI - Finlandia 47
IN - India 27
DE - Germania 20
IE - Irlanda 17
SG - Singapore 13
CA - Canada 6
EU - Europa 5
GB - Regno Unito 3
HK - Hong Kong 3
IR - Iran 3
MD - Moldavia 3
NL - Olanda 3
RU - Federazione Russa 3
BE - Belgio 2
CZ - Repubblica Ceca 2
FR - Francia 2
JP - Giappone 2
TH - Thailandia 2
TN - Tunisia 2
ZA - Sudafrica 2
AR - Argentina 1
AU - Australia 1
EC - Ecuador 1
ES - Italia 1
KW - Kuwait 1
RS - Serbia 1
Totale 1.834
Salva come PNG Salva come JPEG
Città #
Lawrence 219
Princeton 219
Milan 86
Ashburn 74
New York 74
Shanghai 47
Helsinki 46
Pune 22
Dublin 14
Seattle 8
Washington 7
Rome 5
Borås 4
Hamilton 4
Los Angeles 4
West Jordan 4
Angera 3
Ballincollig 3
Chisinau 3
Santa Clara 3
Duchcov 2
Durban 2
Florence 2
Ghent 2
Hanover 2
Hyderabad 2
Padova 2
Panchkula 2
Redwood City 2
Segrate 2
Singapore 2
Tehran 2
Tokyo 2
Torre Del Greco 2
Tualatin 2
Turin 2
Vittoria 2
Wanchai 2
Bangkok 1
Belgrade 1
Campodolcino 1
Castelletto sopra Ticino 1
Castiglion Fiorentino 1
Dalmine 1
Falkenstein 1
Gatchina 1
Giussano 1
Haywards Heath 1
Henderson 1
Isfahan 1
Kuwait City 1
Lainate 1
Lappeenranta 1
London 1
Louth 1
Madignano 1
Madrid 1
Mountain View 1
Nuremberg 1
Paliano 1
Parma 1
Pavia 1
Perm 1
Perugia 1
Quito 1
Reston 1
San Sperate 1
Sydney 1
Taranto 1
Tradate 1
Truccazzano 1
Vancouver 1
Viedma 1
West Hartford 1
Totale 921
Salva come PNG Salva come JPEG
Nome #
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 41
The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients 30
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 30
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls 27
Biobanking for COVID-19 research 25
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy 24
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 22
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection 19
Early diagnosis of HIV infection in infants 18
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 18
VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression 18
Circulating cathodic antigen (CCA) urine rapid test for diagnosis of Schistosoma mansoni infestation: preliminary data of a cohort study of Egyptian patients coming from an endemic area 18
Morphogenesis, evolution and prognostic significance of lymphatic tissue lesions in HIV infection 17
Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy 17
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 17
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients 17
A study of cellular immunity in newborns after prevention of respiratory distress syndrome (RDS). 16
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 16
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 16
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 16
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic 16
Western blot in treated people with HIV-1 chronic infection: frequency of negative HIV-1 pol genes 16
A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients 16
ABC of AIDS: Treatment of infections and antiviral agents 16
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study) 15
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 14
GB Virus C and Survival in Persons with HIV Infection 14
Immunological status in heroin addicts: effects of methadone maintenance treatment 14
Cerebrospinal fluid beta 2-microglobulin in AIDS related central nervous system involvement. 14
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 14
Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy 14
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 14
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 14
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection 13
Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients 13
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 13
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 13
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 13
Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. 13
Evolving treatment implementation among HIV- infected pregnant women and their partners: Results from a national surveillance study in Italy, 2001-2015 13
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 13
HEFFICON: HIV Effectiveness Italian Conference 13
Naive HIV/HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfected patients treated with antiretroviral therapy 12
Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission 12
HLA-associated susceptibility to AIDS: HLA B35 is a major risk factor for Italian HIV-infected intravenous drug addicts 12
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response 12
Clinical and epidemiological aspects of the first 50 cases of AIDS in Milan 12
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients 12
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study 12
Cytomegalovirus infection of the central nervous system in patients with aids: Diagnosis by DNA amplification from cerebrospinal fluid 12
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 12
Risk of HIV infection in recipients of blood and blood products 12
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus 12
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 12
Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals 12
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 12
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 12
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 12
Risk of HIV-related diseases in heterosexuals importing infection from Zaire 11
Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients 11
Diagnosis of toxoplasmic encephalitis in HIV-infected patients 11
Therapeutic trials with HPA23, alpha-IFN and ribavirin in AIDS patients 11
Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor-Based Combination Antiretroviral Therapy: The D:A:D Study 11
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015 11
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 11
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 11
Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine 11
Evaluation of total HIV-DNA changes in HIV-1 infected patients who continue a 2-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-One Study 11
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 11
Impact of HAART on liver histology of HIV/HCV coinfected patients 10
Cytomegalovirus pneumonia in AIDS patients: value of cytomegalovirus culture from BAL fluid and correlation with lung disease 10
Epidemiological aspects of human immunodeficiency virus infection in Milan. 10
Experiences with immunomodulant agents in HIV infections 10
Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption 10
Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV-infected patients 10
T-lymphocyte subsets and delayed type hypersensitivity as classification parameters for HIV infection among drug-addicts 10
Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors 10
Increased hyperglycaemia during cotreatment with pentamidine and corticosteroids in AIDS patients 10
Evaluation of contrast-enhancing brain lesions in AIDS patients by means of Epstein-Barr virus detection in cerebrospinal fluid and 201thallium single photon emission tomography 10
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016 10
Ganciclovir therapy for cytomegalovirus (cmv) infection of the central nervous system in aids patients: Monitoring by cmv dna detection in cerebrospinal fluid 10
Bictegravir 10
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression 10
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 10
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011 10
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 10
Dynamics of the M184V mutation by allele-specific PCR (AS-PCR) in patients receiving lamivudine or emtricitabine monotherapy or undergoing treatment interruption (TI) 10
Durability of a novel salvage therapy in R5 HIV-infected patients: maraviroc, raltegravir, etravirine 10
Carotid vessels lesions in experienced HIV-1-infected subjects affected or not by hypertension and/or diabetes mellitus 10
Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing 9
Benefits of a 12 week physical activity programme on muscle and bone health in people living with HIV 9
Impairment of in vitro natural antibacterial activity in HIV-infected patients 9
Evaluation of the detection of human papillomavirus genotypes in cervical specimens by hybrid capture as screening for precancerous lesions in HIV-positive women 9
Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin 9
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients 9
Long-lasting CCR5 internalization by antibodies in a subset of long-term non progressors: a possible protective effect against disease progression 9
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 9
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism 9
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 9
REAL-LIFE EXPERIENCE OF DAA-BASED REGIMENS PLUS RIBAVIRIN IN CIRRHOTIC PATIENTS COINFECTED WITH HCV AND HIV-1 9
Totale 1.342
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.709
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.709
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012 10 0 0 0 1 0 0 0 0 0 0 1
2020/202191 0 0 1 6 0 14 11 57 1 0 1 0
2021/2022145 0 0 0 77 6 8 8 13 10 7 3 13
2022/20231.203 483 292 102 7 10 125 33 85 48 1 11 6
2023/2024444 7 29 81 49 45 137 13 68 0 15 0 0
Totale 2.087